Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is ...

Trontinemab is one of a class of new medicines aimed at clearing amyloid plaques. The new findings from phase two trials ...

Roche Holding AG plans to test whether an experimental medicine can prevent Alzheimer’s disease symptoms in high-risk people, ...

There is progress to report in the battle against Alzheimer's. While there is still no cure, new tests and new treatments are ...

A new Alzheimer’s drug has been hailed as a major breakthrough after clinical trials showed it could clear the harmful brain ...

Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...

TORONTO -- An investigational antibody drug, designed to cross the blood-brain barrier (BBB) to eliminate amyloid-beta ...

These five upcoming data drops could usher in more effective and convenient therapies for Alzheimer’s disease and open up ...

Older adults who took medications for high blood pressure, high cholesterol and diabetes had slower rates of cognitive ...

Microglia, a type of brain immune cell, can gobble up amyloid beta protein, which clumps together into toxic aggregates ...

Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the ...

Major health news includes Roche's plan to test a drug for Alzheimer's, a US data-sharing initiative in healthcare, Nordic ...